Clinical Trial Update: An Open-Label Study of Ruxolitinib Given With Chemotherapy in Patients With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

A Phase 1 open-label trial evaluating ruxolitinib in combination with chemotherapy for advanced solid tumors, terminated with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer
• Solid Tumors

Drugs mentioned

• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: Incyte Corporation | Conditions: Solid Tumors, Pancreatic Cancer | Phase 1 | Status: TERMINATED | Results posted: 2017-04-13